DermTech, Inc. Appoints New Scientific Advisory Board Members
February 09, 2021 at 03:00 am IST
Share
DermTech, Inc. announced the additions of Lisa Beck and George Han to its scientific advisory board (SAB). The SAB provides important support and advice to the company, which advances its research and development of skin cancer and skin disease tests and treatment. The experience of each member of the SAB in dermatology, skin cancer, genomics or biotech innovations distinguishes them as industry leaders and experts in their respective fields. Lisa Beck, is the co-director of the University of Rochester Medical Center for Allergic Disease Research and has served on the board of directors of the International Eczema Council since 2014. Specializing in the treatment of atopic dermatitis and eczema. Beck is currently serving as President-Elect of the Society of Investigative Dermatology (2020-2021). George Han, currently serves as the System Medical Director for Dermatology and Chief of Teledermatology at the Mount Sinai Health System. Han is the current Vice President of the Dermatologic Society of Greater New York and a member of the Medical Board of the National Psoriasis Foundation. To date, Han has over 50 publications in well-respected journals such as the Journal of the American Academy of Dermatology, the Journal of Investigative Dermatology, the Journal of Infectious Diseases, the British Journal of Dermatology and the American Journal of Pathology. Han remains active in conducting both basic scientific research as well as clinical trials.
DermTech, Inc. is a molecular diagnostic company. The Company is engaged in developing and marketing non-invasive genomics tests to aid in the diagnosis and management of melanoma. Its technology enhances evaluation of lesions suspicious for melanoma using non-invasive sample collection and detecting genomic markers associated with melanoma to identify higher risk lesions or rule out melanoma with a 99% or higher negative predictive value (NPV). It offers DermTech Melanoma Test (the DMT), which is a non-invasive way to enhance evaluation of pigmented lesions suspicious for melanoma. Its genomics platform has been designed to work with its Smart Sticker, which provides an easy and non-invasive way to collect a skin sample, in contrast to the existing standard of care of using a scalpel to biopsy suspicious lesions. It also provides its research services and technology platform on a contract basis to pharmaceutical companies that use the technology to support their clinical trials.
DERMTECH, INC. 
